OPEN Foundation

Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies

Abstract

• Converging lines of evidence from pharmacologic, electrophysiologic, and behavioral
research in animals strongly suggest that activation of cortical 5-hydroxytryptamine-2A
receptors is the most critical step in initiating a cascade of biological events that accounts
for serotonergic hallucinogen (SH) psychoactive properties.
• Psilocybin produces hyperfrontality with divergent prefrontal–subcortical activation in such
a way as to increase cognitive and affective processing in the context of reduced gating
and reduced focus on external stimulus processing.
• In contrast to all other drugs of abuse, SHs are not considered to be capable of producing
sufficient reinforcing effects to cause dependence (addiction) syndromes.
• Given that SHs increase extracellular glutamate levels and activity in the prefrontal–
limbic circuitry, it is possible that a normalization in functional connectivity in this
network through a glutamate-dependent neuroplastic adaptation could produce an
anti-addictive effect.

Ross, S. (2012). Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatric Clinics of North America, 35(2), 357-374. http://dx.doi.org/10.1016/j.psc.2012.04.002
Link to full text

OPEN Foundation

Share This Post

get the latest

The OPEN Minded Newsletter keeps you informed about the latest psychedelic research & news, articles, exclusive events, job opportunities, programmes, and free resources!

By clicking SUBSCRIBE, I confirm to receive emails from the OPEN Foundation and agree with its privacy policy.

Join our upcoming events

Be at the forefront of psychedelic research and therapy

An Introduction to Internal Family Systems in Psychedelic Therapy - Online Event - May 13